Convergent Therapeutics has filed a notice of an exempt offering of securities to raise $40 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Convergent Therapeutics is raising up to $39,999,996.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Philip Kantoff played a…
